Robert Jr. Baltera Acquires 20,000 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera acquired 20,000 shares of the business’s stock in a transaction on Wednesday, July 8th. The shares were purchased at an average cost of $1.99 per share, for a total transaction of $39,800.00. Following the completion of the acquisition, the director directly owned 436,904 shares in the company, valued at approximately $869,438.96. The trade was a 4.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Robert Jr. Baltera also recently made the following trade(s):

• On Thursday, July 9th, Robert Jr. Baltera bought 25,000 shares of Palisade Bio stock. The stock was purchased at an average price of $1.96 per share, with a total value of $49,000.00.
• On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The stock was purchased at an average price of $2.03 per share, with a total value of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were purchased at an average cost of $2.05 per share, for a total transaction of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera acquired 10,000 shares of Palisade Bio stock. The stock was purchased at an average cost of $1.98 per share, with a total value of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera acquired 20,000 shares of Palisade Bio stock. The stock was purchased at an average price of $1.98 per share, with a total value of $39,600.00.

Palisade Bio Stock Performance

Shares of Palisade Bio stock traded down $0.01 during mid-day trading on Friday, hitting $1.96. 3,452,719 shares of the stock were exchanged, compared to its average volume of 4,494,371. Palisade Bio, Inc. has a 12 month low of $0.53 and a 12 month high of $2.85. The company has a 50-day simple moving average of $1.92 and a 200 day simple moving average of $1.92. The company has a market capitalization of $340.22 million, a P/E ratio of -1.94 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Analysts predict that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Weiss Ratings raised Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a research report on Tuesday, June 30th. Wolfe Research began coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Finally, Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Palisade Bio currently has an average rating of “Buy” and a consensus price target of $8.83.

Hedge Funds Weigh In On Palisade Bio

Large investors have recently modified their holdings of the business. Total Clarity Wealth Management Inc. bought a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $70,000. Jefferies Financial Group Inc. purchased a new position in Palisade Bio in the 4th quarter valued at approximately $110,000. Geode Capital Management LLC grew its stake in Palisade Bio by 5,780.7% in the 4th quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after buying an additional 1,538,832 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Palisade Bio during the 4th quarter valued at $1,310,000. Finally, TD Asset Management Inc bought a new stake in Palisade Bio during the 4th quarter valued at $480,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.